CYP19A1 rs2470152: Estrogen Levels and Reproductive Traits
The rs2470152 polymorphism is a single nucleotide variant located in an intron of the CYP19A1 gene on chromosome 15. The CYP19A1 gene encodes aromatase, the rate-limiting enzyme responsible for converting androgens into estrogens. Research associates this variant with subtle shifts in circulating sex hormone levels and potential downstream reproductive phenotypes, though clinical evidence remains limited.
What each genotype means
Lower baseline estrogen association
Carrying two copies of the A allele (sometimes reported as T in minus-strand literature) has been linked in preliminary studies with relatively lower aromatase activity and lower circulating estradiol levels compared to other genotypes. Research exploring reproductive phenotypes such as age at menarche and endometriosis shows modest and inconsistent associations that appear population-specific. These statistical findings represent general research correlations rather than personal diagnostic markers.
Carried by approximately 15% to 22% of individuals across European and East Asian ancestry groups.
Intermediate aromatase activity profile
Carrying one A allele and one G allele (reported as TC on the alternate strand) is associated with intermediate or variable estrogen-to-androgen ratios in clinical research. Some reproductive endocrinology studies note subtle differences in circulating hormone balance, though findings remain mixed and do not establish a definitive risk for reproductive conditions. These findings reflect small statistical variations across study cohorts rather than health outcomes.
Carried by approximately 45% to 55% of individuals across major global populations, representing the most common genotype.
Higher baseline estrogen association
Carrying two copies of the G allele (frequently annotated as CC on the complementary strand) is associated with higher aromatase enzyme expression and modestly higher circulating estradiol and estrone concentrations in observational cohorts. While some candidate-gene studies have explored links between this genotype, menarche timing, and estrogen-dependent conditions, overall evidence remains limited and conflicting. These associations describe minor hormonal shifts across populations rather than health diagnoses.
Carried by approximately 25% to 36% of individuals in European and East Asian populations.
Genomic Context and Molecular Characterization
The single nucleotide polymorphism rs2470152 is located on human chromosome 15 within the non-coding intronic region of the CYP19A1 gene. As an intronic variant, it does not directly alter the amino acid sequence of the resulting protein product. Instead, variants in this region often function by altering transcription factor binding sites, modifying splicing efficiency, or serving as a proxy in linkage disequilibrium with other functional non-coding variants. The typical alleles found at this position are thymine (T) and cytosine (C). Because it resides in an intronic segment, researchers classify it primarily as a candidate regulatory variant or a tag SNP rather than a disruptive coding mutation.
Biological Function of the CYP19A1 Gene
The CYP19A1 gene encodes cytochrome P450 family 19 subfamily A member 1, widely recognized as the aromatase enzyme, as detailed by MedlinePlus Genetics (https://medlineplus.gov/genetics/gene/cyp19a1/). Aromatase serves a foundational role in human endocrine biology by catalyzing the final, irreversible conversion of androgens into estrogens—specifically transforming testosterone into estradiol and androstenedione into estrone. This enzymatic conversion occurs across multiple body tissues, including the ovaries, testes, adipose tissue, placenta, and brain. Because estrogen signaling regulates pubertal timing, reproductive tissue maintenance, bone mineral density, and vascular health, even modest shifts in aromatase expression or catalytic efficiency can modulate downstream hormone-dependent traits across life stages.
Association Research: Estrogen Levels and Reproductive Phenotypes
Candidate gene studies and genome-wide association studies (GWAS) have linked rs2470152 and adjacent CYP19A1 polymorphisms to variations in circulating estradiol concentrations and estrogen-to-testosterone ratios. Research featured in PubMed (https://pubmed.ncbi.nlm.nih.gov/19818337/) shows that while rs2470152 emerged as a strong predictor of circulating estradiol in European cohorts, its individual association in East Asian cohorts was modest, appearing more impactful when analyzed as part of multi-marker haplotypes. Additional exploratory studies have examined the variant's potential connection to reproductive timing, including age at menarche, and estrogen-driven conditions such as endometriosis. However, the scientific evidence supporting a direct causative link to endometriosis remains limited and shows inconsistent effect sizes across different ethnic groups.
Population Frequency and Diversity
Allele frequencies for rs2470152 demonstrate noticeable variation across global populations. In individuals of European ancestry, the minor allele frequency is approximately 0.40, making heterozygous and homozygous alternate genotypes common in these groups. In East Asian and African populations, allele distributions and surrounding linkage disequilibrium architectures differ, which often alters how strongly the variant tags functional regulatory signals. Because local genomic architecture varies by ancestry, an association observed with rs2470152 in one ancestral population does not necessarily indicate the same magnitude of phenotypic effect in individuals of different heritage.
Clinical Utility and Lifestyle Considerations
At present, rs2470152 is an exploratory research biomarker with limited clinical evidence and is not approved for independent diagnostic or predictive medical use. Carrying a particular genotype does not confirm that an individual will develop endometriosis, experience irregular puberty timing, or exhibit abnormal sex hormone levels. Clinical endocrine health is heavily shaped by lifestyle factors, body mass index, nutrition, and environmental influences. Anyone with concerns regarding reproductive symptoms or hormone balance should seek guidance from a qualified healthcare provider. Furthermore, patients undergoing endocrine treatments, such as aromatase inhibitor therapy, should consult their physician or clinical pharmacist regarding drug efficacy and safety rather than relying on direct-to-consumer genetic profiles.
How common is this variant?
The minor allele frequency for rs2470152 is approximately 0.40 in populations of European ancestry, with common representation of all three genotypes (TT, TC, and CC) across global cohorts.
Frequently asked questions
Does having the rs2470152 variant mean I have or will develop endometriosis?
No, it does not. The scientific evidence connecting rs2470152 to endometriosis is classified as limited and inconsistent across different ancestral groups. Endometriosis is a complex condition driven by dozens of genetic variants combined with hormonal and environmental influences.
Can rs2470152 test results determine my estrogen levels?
Genetic tests for rs2470152 cannot reliably predict or replace a clinical laboratory measurement of your hormone levels. While statistical associations exist between this variant and average estradiol levels in large population studies, an individual's actual circulating hormones are predominantly determined by age, circadian rhythm, body composition, and medical factors.
What is the CYP19A1 gene's main biological purpose?
The CYP19A1 gene codes for aromatase, an enzyme that converts androgen hormones into estrogen hormones throughout the body. This process is essential for normal reproductive function, healthy bone density, and the regulation of secondary sex characteristics in both women and men.
Should I change any medications or aromatase inhibitors based on this SNP?
No. Current clinical guidelines do not recommend altering medications, dosages, or aromatase inhibitor regimens based on rs2470152 status alone. Always consult your treating physician or clinical pharmacist before making any changes to prescribed hormonal therapies.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2470152?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP19A1
This variant in the aromatase gene is associated with circulating estrogen levels and influences the timing of natural menopause and cardiovascular risk profiles in postmenopausal women.
This regulatory variant in the aromatase gene is associated with circulating estradiol levels and the timing of natural menopause.
Pathogenic variant causing aromatase deficiency characterized by female pseudohermaphroditism, maternal virilization during pregnancy, and absent pubertal development.
Intronic variant in the CYP19A1 gene associated with circulating estradiol and follicle-stimulating hormone (FSH) levels in men.
This variant in the aromatase gene is associated with variations in sex hormone levels and potential risk modulation for hormone-dependent reproductive cancers.
Affects aromatase activity, influencing efficacy and toxicity in hormone-sensitive cancer treatments.